Tirzepatide Muscle Loss: What the SURMOUNT-1 DXA Data Shows
Most searches for tirzepatide muscle loss are really asking one thing: is this drug eating my muscle? The trial data says no, not in the way people fear. In the SURMOUNT-1 DXA substudy, participants on tirzepatide lost 21.3% of body weight over 72 weeks, and roughly 75% of that loss came from fat mass with 25% from lean mass. Placebo showed the same rough split.
That last detail is the interesting one. Tirzepatide moved far more total weight, so the absolute kilograms of lean mass lost were larger, but it did not tilt the ratio toward lean tissue. This guide walks through the numbers, the population behind each one, and what the Zepbound and Mounjaro labels each do and do not say. Start with the tirzepatide guide for background.
Key Takeaways
- The fat-to-lean split matched placebo. Roughly 75% of the weight lost was fat and 25% was lean mass, in both the tirzepatide and placebo arms of the SURMOUNT-1 DXA substudy.
- Lean mass fell 10.9% on tirzepatide over 72 weeks, against 2.6% on placebo. Total body weight fell 21.3% versus 5.3%, so much more tissue moved overall.
- Lean mass is not muscle. DXA lean mass includes body water, glycogen-bound fluid, organs, and connective tissue, so it is not a muscle measurement in either direction.
- Two different numbers, two different denominators. The 10.9% is change within the lean compartment. The 25% is lean mass as a share of the weight lost. They are not interchangeable.
- Zepbound's label addresses body composition in one sentence. Mounjaro's label does not address it at all.
- Resistance training and adequate protein are the levers with the most evidence, and matter more when total weight loss is large.
Approval Status
Tirzepatide is FDA approved, sold by Eli Lilly as Mounjaro for type 2 diabetes (2022) and Zepbound for weight management (2023). Because it is approved, this article quotes the prescribing information directly.
SURMOUNT-1 DXA substudy, n=160 of 2,539, adults with obesity or overweight, 72 weeks (Look et al., 2025).
Does Tirzepatide Cause Muscle Loss? The Short Answer
Tirzepatide has no known mechanism for breaking down muscle tissue. It produces a large, sustained calorie deficit through the GLP-1 and GIP receptors, and any large deficit draws on both fat and lean tissue. That is true of dieting, surgery, and every drug in this class, so the useful question is not whether lean mass falls but what fraction of the loss is lean.
The SURMOUNT-1 DXA substudy answered that directly. Over 72 weeks, adults with obesity or overweight taking tirzepatide lost 21.3% of body weight against 5.3% on placebo, and roughly 75% of the weight lost was fat mass with 25% lean mass in both arms. A drug that selectively degraded muscle would have shifted that ratio. It did not.
The honest framing: tirzepatide moves much more weight than placebo, so the absolute kilograms of lean tissue lost are larger. But what came off looks like ordinary weight loss, not something the drug does uniquely to muscle. That distinction, absolute amount versus proportion, is where most of the confusion online comes from.
Lean Mass Is Not the Same as Muscle
Every headline figure here comes from a body composition scan, and scans do not measure muscle directly. DXA sorts the body into three buckets: fat mass, bone mineral, and lean soft tissue. That third bucket, shortened to "lean mass," holds skeletal muscle plus body water, glycogen-bound fluid, organ tissue, and connective tissue. Muscle is a large share of it, not all of it.
Because glycogen binds water, a drop in carbohydrate intake shrinks glycogen stores and pulls measured lean mass down with them, without any contractile muscle being lost. A lean mass reading is therefore not a muscle reading, which cuts both ways and does not license assuming muscle loss was smaller. How coarse the bucket is shows up in the literature itself: a 2025 systematic review of tirzepatide's effect on skeletal muscle mass (Hidalgo Ramos and colleagues, Cureus) works from the standard definition of lean mass as body weight minus fat, which is why no study using it can report a muscle-specific number.
MRI takes a different angle, measuring the volume of specific muscle groups and how much fat has infiltrated the tissue itself. That is muscle quality rather than quantity, from a separate trial in a different population, covered below.
Model Your Tirzepatide Titration
See how tirzepatide accumulates across your dose schedule before you talk through pace with your prescriber.
What the SURMOUNT-1 DXA Substudy Actually Shows
Study Design and Population
SURMOUNT-1 enrolled 2,539 adults with obesity or overweight. Within it, 160 participants had usable DXA scans at both baseline and week 72: 124 across the pooled tirzepatide doses of 5, 10, and 15 mg, and 36 on placebo. The substudy group was 73% female, with a mean weight of 102.5 kg and a mean BMI of 38.0. Look and colleagues published the results in Diabetes, Obesity and Metabolism in 2025. The trial and the analysis were funded by Eli Lilly and Company, which makes both tirzepatide brands.
The Numbers
| Measure (change from baseline to week 72) | Tirzepatide (pooled) | Placebo |
|---|---|---|
| Body weight | -21.3% | -5.3% |
| Fat mass | -33.9% | -8.2% |
| Lean mass | -10.9% | -2.6% |
All comparisons p<0.001. Source: Look et al., Diabetes Obes Metab, 2025.
Two Percentages, Two Different Denominators
Do not try to derive one figure from the other. The -33.9% and -10.9% above are changes measured within each compartment: fat mass shrank by a third of the fat a person started with, and lean mass shrank by roughly a tenth of the lean tissue they started with. The 75/25 split is a different calculation entirely: it describes what share of the kilograms that came off was fat and what share was lean. Baseline fat and lean mass were roughly comparable in this group, about 47 kg of fat against 51 kg of lean tissue. Fat dominates the kilograms lost not because there was more of it to start with, but because it fell about three times faster in percentage terms: a third of the fat compartment against a tenth of the lean one. Arithmetic that mixes the two denominators gives a wrong answer.
The Key Finding: The Proportion Stayed the Same as Placebo
This is the most defensible claim in tirzepatide's body composition literature, and not the one most articles lead with. Of the body weight lost, approximately 75% was fat mass and 25% was lean mass, for both tirzepatide and placebo. The drug produced four times the weight loss without changing the recipe of what came off.
A 2025 clinical roundtable led by Mechanick and colleagues, reviewing strategies for minimising muscle loss on incretin drugs, also cites the same 10.9% lean mass figure from the SURMOUNT-1 DXA subgroup. That is the same underlying dataset, not a second measurement of it, so treat it as one finding reported twice. That paper was funded by Abbott Nutrition, a nutrition products manufacturer, which is worth knowing when reading its dietary recommendations.
What the Subgroup Data Does and Does Not Tell Us
The authors ran three post-hoc subgroups. Age and sex barely move: fat was 74% of the weight lost under age 50, 75% from 50 to 65, and 76% at 65 and over; by sex, 75% for women and 73% for men. The third matters more. Split by how much weight people lost, the fat share ran 70%, 73% and 76% across ascending tertiles, and the paper flags that 70% as a departure from consistency. Note the direction: the people who lost least gave up the largest lean share, so the proportion is not a constant.
Two caveats on precision. The results section reports 74/26 for tirzepatide and 75/25 for placebo, so the "roughly 75/25 in both arms" used throughout this article is a deliberate rounding of two close but non-identical figures. And the breakdowns are one variable at a time: there is no joint cell, so a number for women over 65 is not in the paper and anyone quoting one has made it up. With 36 people in the placebo arm, these slices are directional rather than definitive.
What the SURPASS-3 MRI Data Shows About Muscle Quality in Type 2 Diabetes
Everything above came from SURMOUNT-1. The next numbers come from a different trial programme, in a different population, against a different comparator, using a different imaging method, and the two must be kept apart.
The SURPASS-3 MRI substudy, published by Sattar and colleagues in The Lancet Diabetes and Endocrinology in 2025, studied adults with type 2 diabetes rather than adults with obesity. Its comparator was daily insulin degludec, not placebo. Of 296 people enrolled in the substudy, 246 had valid week 52 scans, split across 190 on tirzepatide and 56 on insulin degludec. Mean age was 56 and mean BMI 33.4. This trial was also funded by Eli Lilly and Company.
Two findings came out of it. Muscle fat infiltration, the fat that accumulates inside muscle tissue, fell by a mean of 0.36 percentage points on tirzepatide, while the insulin degludec group showed no significant change. Thigh muscle volume fell 0.64 litres on tirzepatide, a significant difference from insulin degludec, which showed a small increase. The authors concluded that tirzepatide was associated with potentially favourable changes in muscle fat infiltration alongside muscle volume reductions broadly in line with the usual relationship between muscle volume and body weight.
One endpoint cuts the other way. The authors also reported a muscle volume Z score, which adjusts for sex, height, weight and BMI and so answers whether muscle fell by more than body size predicts. It dropped 0.22 (95% CI -0.29 to -0.15, p<0.0001). Raw volume change tracked what weight loss predicts at every dose (pooled -0.04 L, p=0.22); it was the Z score that fell further than the population estimate at 15 mg (mean difference -0.18, p=0.0016). So at the top dose muscle shrank by slightly more than body size predicts on the adjusted measure, not on raw volume.
Read this as a quality signal, not a growth signal. Less fat inside muscle tissue is favourable, and a different thing from muscle getting bigger or stronger. Nothing here shows tirzepatide builds muscle. These figures also cannot be combined with the SURMOUNT-1 numbers: a percentage-point change in fat infiltration and a litre of muscle volume in adults with type 2 diabetes measure different things in different people than a lean mass percentage in adults with obesity.
What the Mounjaro and Zepbound Labels Say About Muscle
Tirzepatide is sold under two brand names with two separate prescribing documents, and they do not say the same thing here. The distinction gets flattened whenever someone writes "the label says" without naming which one.
The Zepbound prescribing information contains exactly one sentence on the subject, in section 12.2 on pharmacodynamics: "Tirzepatide lowers body weight with greater fat mass loss than lean mass loss." That is directional, with no figures attached.
The Mounjaro prescribing information says nothing on the subject: no reference to lean mass, fat mass, body composition, or sarcopenia. Its only use of the word muscle is in the injection instructions, warning against injecting into a muscle, which is technique rather than body composition. For brand context, see the Mounjaro overview.
What Actually Protects Muscle During Tirzepatide Treatment
Resistance Training
Progressive resistance training has the most evidence behind it, regardless of which incretin drug is involved. The 2025 Mechanick roundtable points to standard public health activity guidance: muscle-strengthening activity on at least two days a week, alongside 150 to 300 minutes of moderate intensity activity. That is general population guidance rather than a tirzepatide protocol, and applying it is a conversation for a prescriber or qualified trainer. Locatelli and colleagues reached a similar conclusion in Diabetes Care.
Protein Intake
Adequate protein supports lean tissue retention in a calorie deficit. The Mechanick roundtable relays two figures measured on different scales, which matters on a page about denominators. One is a Joslin Diabetes Center range of roughly 1.0 to 1.5 grams per kilogram of adjusted body weight, meaning ideal weight plus about a quarter of the excess. The other is roughly 1.2 to 1.5 grams per kilogram of actual body weight for healthy adults over 65. At a BMI near 38 those scales give noticeably different gram targets, so they are not two ends of one range. Both are population-level figures from a nutrition-manufacturer-funded paper, not personalised targets, and converting either into a number is work for a doctor or registered dietitian. Appetite suppression is the mechanism doing the work here, so hitting any target takes deliberate effort. If digestive effects are cutting into intake, the tirzepatide side effects guide covers the pattern.
Titration Pace
This is an inference, not a trial finding. Less total weight lost means fewer absolute kilograms of lean tissue lost, which is the argument for slower escalation or a lower maintenance dose. But the tertile data complicates it: those who lost least gave up the largest lean share, so a smaller loss is not automatically a cleaner one. No trial has tested titration speed against body composition, so treat it as a discussion point, not a protocol. The tirzepatide dosing guide covers the standard schedule.
Tirzepatide Muscle Loss and Sarcopenia Risk in Older Adults
Age changes the stakes of any significant weight loss. Sarcopenia, the age-related decline in muscle mass and strength, progresses independently of medication, which is why clinicians treat older adults as a distinct group. The Mechanick roundtable makes this explicit by carrying a separate protein figure for healthy adults over 65, roughly 1.2 to 1.5 grams per kilogram of actual body weight, rather than one guideline for all ages. That is not a reason to avoid treatment, and obesity itself carries substantial risk in older adults. The point is narrower: the same lean mass percentage carries different consequences at 70 than at 35.
Does Tirzepatide Build Muscle?
No. Tirzepatide is a dual GLP-1 and GIP receptor agonist, and neither pathway has an established role in muscle protein synthesis. No trial has reported muscle growth as an outcome, and both body composition datasets covered here show lean mass or muscle volume falling. The SURPASS-3 fat infiltration finding gets recycled online as evidence of muscle improvement, but less fat inside muscle tissue, measured in type 2 diabetes against an insulin comparator, says nothing about muscle size or strength. Building muscle takes resistance training and enough protein, on the drug or off it.
What We Still Do Not Know About Tirzepatide Muscle Loss
- No head-to-head body composition trial. SURPASS-2 compared tirzepatide against semaglutide on blood glucose and weight endpoints, not DXA body composition. A numeric claim that one loses more lean mass than the other has no trial behind it, and there is no head-to-head against retatrutide either, as our retatrutide muscle mass article states from the other side.
- The MRI muscle data is type 2 diabetes only. Nobody has replicated the SURPASS-3 findings in a weight-loss population without diabetes.
- Nothing past 72 weeks. Whether lean mass stabilises, partially recovers, or keeps declining on long-term treatment is unmeasured.
- How much of the lean loss is contractile muscle. DXA cannot separate muscle from water and organ tissue, so no muscle-specific figure follows from it. The Mechanick roundtable declines the conversion and, where it estimates, puts muscle loss at 10% or more.
Separately, researchers are testing drugs designed to be added to weight-loss treatment specifically to reduce lean mass loss. One candidate, apitegromab, reported phase 2 results in Nature Medicine in 2026. It is not a GLP-1, not tirzepatide, and not available, so it is research to watch rather than part of anyone's plan.
Planning Your Titration With the GLP3Planner Calculator
The GLP3Planner tirzepatide calculator models how the drug accumulates across a titration schedule, turning a vague question about pace into a curve you can bring to an appointment. It is a planning tool, not medical advice, and it does not measure body composition. Pair it with periodic DXA scans or strength benchmarks.
Video: a physician-led walkthrough of what the clinical trials report about muscle loss on GLP-1 medications.
Frequently Asked Questions
Does tirzepatide cause muscle loss?
Tirzepatide does not selectively break down muscle. In the SURMOUNT-1 DXA substudy, participants lost 21.3% of body weight over 72 weeks, split roughly 75% fat mass and 25% lean mass, the same ratio seen on placebo. Lean mass also includes water and organ tissue, not muscle alone.
How much muscle do you lose on tirzepatide?
In the SURMOUNT-1 DXA substudy of 160 adults with obesity or overweight, lean mass fell 10.9% over 72 weeks on tirzepatide against 2.6% on placebo. That is the change within the lean compartment, which also counts body water, connective tissue, and organs. How much of it was muscle cannot be derived from DXA in either direction.
What does the Zepbound label say about muscle loss?
The Zepbound prescribing information states in section 12.2 that tirzepatide lowers body weight with greater fat mass loss than lean mass loss. That single directional sentence, with no figures, is the whole of it. The Mounjaro prescribing information does not mention lean mass or body composition at all.
How do I avoid losing muscle on tirzepatide?
The two most evidence-supported steps are progressive resistance training and adequate protein intake. A 2025 clinical roundtable relays protein guidelines on two different scales, one keyed to adjusted body weight and a separate one for adults over 65 keyed to actual body weight, so translating either into a personal target is work for a doctor or registered dietitian. Titration pace is worth raising with a prescriber, though no trial has tested it against body composition.
Is tirzepatide muscle loss the same as with semaglutide?
No head-to-head DXA trial has compared their lean mass proportions, so a numeric comparison is not supported. SURPASS-2 did compare the two drugs, but on blood glucose and weight endpoints rather than body composition. For class-wide context, a 2024 Diabetes Care review by Locatelli and colleagues puts lean mass loss on incretin therapy at around 10 percent of the lean compartment, or about 6 kg, comparable to a decade or more of aging.
What is myosteatosis and does tirzepatide reduce it?
Myosteatosis is fat accumulating inside muscle tissue, which can impair muscle quality. The SURPASS-3 MRI substudy, in adults with type 2 diabetes, found muscle fat infiltration fell by 0.36 percentage points on tirzepatide against no significant change on insulin degludec. That is a quality finding, and it has not been replicated in a weight-loss population.
Plan Your Tirzepatide Dosing
Map your titration schedule and see when levels plateau.
References
- Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729. (Funded by Eli Lilly and Company.) [PubMed]
- Sattar N, Neeland IJ, Dahlqvist Leinhard O, et al. Tirzepatide and muscle composition changes in people with type 2 diabetes (SURPASS-3 MRI substudy). Lancet Diabetes Endocrinol. 2025;13(6):482-493. (Funded by Eli Lilly and Company.) [PubMed]
- Mechanick JI, Butsch WS, Christensen SM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025;26(1):e13841. (Funded by Abbott Nutrition.) [PubMed]
- Hidalgo Ramos RA, Hong I, Ortiz M, et al. Effects of tirzepatide on skeletal muscle mass in adults: a systematic review. Cureus. 2025;17(7):e89020. [PubMed]
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. [NEJM]
- Locatelli JC, Costa JG, Haynes A, et al. Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? Diabetes Care. 2024;47(10):1718-1730. [PubMed]
- ZEPBOUND (tirzepatide) Prescribing Information, section 12.2 Pharmacodynamics. Eli Lilly and Company. Revised 4/2026. [DailyMed]
- MOUNJARO (tirzepatide) Prescribing Information. Eli Lilly and Company. Revised 4/2026. [DailyMed]
- Pratley RE, Denham DS, Trivedi R, et al. Apitegromab for lean mass preservation during tirzepatide-induced weight loss: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Med. 2026. [PubMed]
Medical Disclaimer
This article is for informational and educational purposes only and does not constitute medical advice. Nothing here is a personalised nutrition, exercise, or dosing recommendation. Do not start, stop, or modify any medication regimen without consulting a qualified healthcare provider. Individual results vary. Always discuss treatment options, risks, benefits, and alternatives with your doctor.